The Peptide Processing Problem
You've built a real peptide business. Legitimate products, proper labeling, maybe a telemedicine model or compounding pharmacy partnership. Your customers are happy. Revenue is growing.
Then your processor shuts you down.
No warning. Funds held for 90 days. A form letter about "prohibited products" from a company that approved you three months ago. And now you're scrambling to find another solution while your business bleeds revenue every day you can't accept payments.
This happens constantly in the peptide space. It happens because most payment processors don't understand the difference between a legitimate peptide company and a fly-by-night operation selling unregulated substances. They see "peptides" on the application, flag it as high-risk, and either decline you outright or approve you with someone in compliance who's one Google search away from terminating the account.
Why Most Processors Get It Wrong
The peptide industry sits at an intersection of health, wellness, and regulatory grey area that makes generic payment processors uncomfortable. Here's what they stumble on:
Product Classification Confusion
BPC-157, TB-500, semaglutide, and other peptides can be sold legally under multiple frameworks: research-use only, compounded prescriptions through licensed pharmacies, or through telehealth platforms with prescriber oversight. Each model has different compliance requirements, and each one requires different documentation for underwriting. A processor that doesn't know the difference between these models will treat them all the same, and that usually means denial.
Marketing Claim Landmines
The FDA hasn't approved most peptides for therapeutic use. That means every health claim on your website, every testimonial about results, every before-and-after photo is a potential red flag for an underwriter reviewing your application. The problem isn't that you're doing anything wrong. The problem is that underwriters at generic processors don't know where the line is, so they reject the whole application instead of asking the right questions.
The Subscription Chargeback Trap
Most peptide companies run subscription models because their customers reorder monthly. Subscriptions in a "high-risk" category means elevated chargeback exposure, and most processors don't configure the account correctly from the start. No chargeback alerts, no descriptor optimization, no retry logic tuning. Then when disputes tick up, they terminate you for exceeding thresholds they never helped you manage.
The real issue: You're not actually high-risk. You're just being treated by processors who don't have the underwriting relationships or industry knowledge to place you correctly.
What Proper Peptide Processing Looks Like
Getting a stable peptide merchant account comes down to three things: the right acquiring bank, a properly built compliance file, and proactive chargeback management.
The Right Acquiring Bank
There are acquiring banks that specifically underwrite peptide businesses. They understand the product category, the regulatory framework, and the business models. They're not going to shut you down because someone in their compliance department Googled "BPC-157" and got nervous. But these banks are selective. They want to see that you've done the compliance work before they review your application.
A Pre-Built Compliance File
The application that gets approved looks different from the one that gets denied. It includes:
- Product classification documentation showing your legal framework (research-use, compounding, telehealth)
- COAs (certificates of analysis) from third-party labs demonstrating purity and sterility
- Supply chain documentation for your API sourcing
- Website review confirming compliant marketing language
- Prescriber network documentation (if applicable)
- Refund policy and subscription terms that meet card network requirements
When this file arrives on an underwriter's desk, it answers every question before they can ask it. That's the difference between a 5-day approval and a rejection letter.
Chargeback Infrastructure From Day One
Rates for peptide merchant accounts typically fall between 4.5% and 7.5%, depending on your volume and risk profile. But the rate doesn't matter if your account gets terminated for chargebacks. Proper setup includes Ethoca and Verifi chargeback alerts, optimized billing descriptors, and subscription management that gives customers clear cancellation pathways. Most of our peptide clients process with no rolling reserve because the account is configured correctly from the start.
The Cost of Getting This Wrong
Every day without processing costs you revenue. But it goes deeper than that. When a processor terminates your account, that termination goes on the MATCH list (the industry's blacklist). Future applications get harder. Rates get higher. Reserves get steeper. One bad processor relationship creates a compounding problem that follows your business for years.
Getting placed with the right acquiring bank the first time, with a properly built compliance package, is the difference between a stable processing relationship and a cycle of shutdowns and scrambles.